{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T09:28:49Z","timestamp":1795080529420,"version":"4.10.2"},"reference-count":198,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003083","name":"European Association of Urology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003083","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.eururo.2024.07.027","type":"journal-article","created":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T15:25:55Z","timestamp":1723908355000},"page":"531-549","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":363,"title":["European Association of Urology Guidelines on Non\u2013muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)\u2014A Summary of the 2024 Guidelines Update"],"prefix":"10.1016","volume":"86","author":[{"given":"Paolo","family":"Gontero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Birtle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otakar","family":"Capoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Comp\u00e9rat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 L.","family":"Dominguez-Escrig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Liedberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paramananthan","family":"Mariappan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Masson-Lecomte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugh A.","family":"Mostafid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Pradere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavan P.","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas W.G.","family":"van Rhijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Seisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Soria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktor","family":"Soukup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evanguelos N.","family":"Xylinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2024.07.027_b0005","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/bmj.39493.646875.AE","article-title":"Going from evidence to recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2024.07.027_b0010","series-title":"Estimated number of new cases in 2020, worldwide, both sexes, all ages","author":"International Agency for Research on Cancer","year":"2021"},{"key":"10.1016\/j.eururo.2024.07.027_b0015","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00428-015-1739-2","article-title":"Clinicopathological characteristics of urothelial bladder cancer in patients less than 40 years old","volume":"466","author":"Comperat","year":"2015","journal-title":"Virchows Arch"},{"key":"10.1016\/j.eururo.2024.07.027_b0020","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","article-title":"Epidemiology and risk factors of urothelial bladder cancer","volume":"63","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0025","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.eururo.2020.09.006","article-title":"Global trends of bladder cancer incidence and mortality, and their associations with tobacco use and gross domestic product per capita","volume":"78","author":"Teoh","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0030","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s00420-013-0916-3","article-title":"Screening for bladder cancer with urinary tumor markers in chemical workers with exposure to aromatic amines","volume":"87","author":"Pesch","year":"2014","journal-title":"Int Arch Occup Environ Health"},{"key":"10.1016\/j.eururo.2024.07.027_b0035","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/ijc.29062","article-title":"The prognostic value of family history among patients with urinary bladder cancer","volume":"136","author":"Egbers","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.eururo.2024.07.027_b0040","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/ijc.28693","article-title":"Comprehensive analyses of DNA repair pathways, smoking and bladder cancer risk in Los Angeles and Shanghai","volume":"135","author":"Corral","year":"2014","journal-title":"Int J Cancer"},{"key":"10.1016\/j.eururo.2024.07.027_b0045","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/jnci\/djx237","article-title":"Familial cancer clustering in urothelial cancer: a population-based case-control study","volume":"110","author":"Martin","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2024.07.027_b0050","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1158\/1055-9965.EPI-14-0059","article-title":"Increased lung and bladder cancer incidence in adults after in utero and early-life arsenic exposure","volume":"23","author":"Steinmaus","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.eururo.2024.07.027_b0055","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1002\/ijc.31720","article-title":"Potential effect modifiers of the arsenic-bladder cancer risk relationship","volume":"143","author":"Koutros","year":"2018","journal-title":"Int J Cancer"},{"key":"10.1016\/j.eururo.2024.07.027_b0060","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1007\/s00345-023-04380-5","article-title":"External beam radiotherapy combination is a risk factor for bladder cancer in patients with prostate cancer treated with brachytherapy","volume":"41","author":"Minami","year":"2023","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0065","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s11255-016-1491-9","article-title":"WHO 1973 grade 3 and infiltrative growth pattern proved, aberrant E-cadherin expression tends to be of predictive value for progression in a series of stage T1 high-grade bladder cancer after organ-sparing approach","volume":"49","author":"Otto","year":"2017","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.eururo.2024.07.027_b0070","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.eururo.2011.10.026","article-title":"A new and highly prognostic system to discern T1 bladder cancer substage","volume":"61","author":"van Rhijn","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0075","unstructured":"WHO Classification of Tumours Editorial Board. WHO classification of tumours. Urinary and male genital tumours. ed. 5. Vol. 8. International Agency for Research on Cancer; 2022."},{"key":"10.1016\/j.eururo.2024.07.027_b0080","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1080\/21681805.2021.1928746","article-title":"The diagnostic challenge of suspicious or positive malignant urine cytology findings when cystoscopy findings are normal: an outpatient blue-light flexible cystoscopy may solve the problem","volume":"55","author":"Andersson","year":"2021","journal-title":"Scand J Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0085","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S1078-1439(99)00020-4","article-title":"Updated concepts and treatment of carcinoma in situ","volume":"4","author":"Lamm","year":"1998","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2024.07.027_b0090","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/his.14764","article-title":"What's new in WHO fifth edition\u2014urinary tract","volume":"81","author":"Comp\u00e9rat","year":"2022","journal-title":"Histopathology"},{"key":"10.1016\/j.eururo.2024.07.027_b0095","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.eururo.2017.04.015","volume":"72","author":"Soukup","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0100","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.euo.2020.12.002","article-title":"Prognostic value of the WHO1973 and WHO2004\/2016 classification systems for grade in primary Ta\/T1 non-muscle-invasive bladder cancer: a multicenter European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel study","volume":"4","author":"van Rhijn","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2024.07.027_b0105","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.urology.2005.10.028","article-title":"Review pathology in a diagnostic bladder cancer trial: effect of patient risk category","volume":"67","author":"Witjes","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2024.07.027_b0110","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.eururo.2009.03.052","article-title":"Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: a multicentre study comparing the 1973 and 2004 World Health Organisation classifications","volume":"57","author":"May","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0115","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1464-410X.2009.09100.x","article-title":"Pathological stage review is indicated in primary pT1 bladder cancer","volume":"106","author":"van Rhijn","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2024.07.027_b0120","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/his.12214","article-title":"An interobserver reproducibility study on invasiveness of bladder cancer using virtual microscopy and heatmaps","volume":"63","author":"Comperat","year":"2013","journal-title":"Histopathology"},{"key":"10.1016\/j.eururo.2024.07.027_b0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083192","article-title":"Reproducibility and prognostic value of WHO1973 and WHO2004 grading systems in TaT1 urothelial carcinoma of the urinary bladder","volume":"9","author":"Mangrud","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.eururo.2024.07.027_b0130","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.euo.2019.09.003","volume":"2","author":"Veskimae","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2024.07.027_b0135","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/bju.14417","article-title":"A systematic review and meta-analysis of the impact of lymphovascular invasion in bladder cancer transurethral resection specimens","volume":"123","author":"Mari","year":"2019","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2024.07.027_b0140","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.jmoldx.2022.05.006","article-title":"The Lund molecular taxonomy applied to non-muscle-invasive urothelial carcinoma","volume":"24","author":"Marzouka","year":"2022","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.eururo.2024.07.027_b0145","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/bju.13345","article-title":"Microscopic haematuria at time of diagnosis is associated with lower disease stage in patients with newly diagnosed bladder cancer","volume":"117","author":"Ramirez","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2024.07.027_b0150","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00261-017-1249-6","article-title":"Bladder cancer diagnosis with CT urography: test characteristics and reasons for false-positive and false-negative results","volume":"43","author":"Trinh","year":"2018","journal-title":"Abdom Radiol (NY)"},{"key":"10.1016\/j.eururo.2024.07.027_b0155","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1007\/s00330-006-0386-z","article-title":"Understanding multislice CT urography techniques: many roads lead to Rome","volume":"16","author":"Nolte-Ernsting","year":"2006","journal-title":"Eur Radiol"},{"key":"10.1016\/j.eururo.2024.07.027_b0160","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.juro.2018.04.065","article-title":"Can renal and bladder ultrasound replace computerized tomography urogram in patients investigated for microscopic hematuria?","volume":"200","author":"Tan","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0165","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.3390\/cancers12102994","article-title":"Systematic Review and Meta-Analysis of Vesical Imaging-Reporting and Data System (VI-RADS) inter-observer reliability: an added value for muscle invasive bladder cancer detection","volume":"12","author":"Del Giudice","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.eururo.2024.07.027_b0170","doi-asserted-by":"crossref","first-page":"66.e25","DOI":"10.1016\/j.urolonc.2014.06.008","article-title":"Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer","volume":"33","author":"Yafi","year":"2015","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2024.07.027_b0175","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1111\/j.1464-410X.2006.06036.x","article-title":"Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder","volume":"97","author":"Karakiewicz","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2024.07.027_b0180","series-title":"The Paris system for reporting urinary cytology","author":"Wojcik","year":"2022"},{"key":"10.1016\/j.eururo.2024.07.027_b0185","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.euo.2021.10.003","article-title":"Diagnostic accuracy of novel urinary biomarker tests in non-muscle-invasive bladder cancer: a systematic review and network meta-analysis","volume":"4","author":"Laukhtina","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2024.07.027_b0190","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1111\/bju.14673","article-title":"Diagnostic accuracy, clinical utility and influence on decision-making of a methylation urine biomarker test in the surveillance of non-muscle-invasive bladder cancer","volume":"123","author":"D'Andrea","year":"2019","journal-title":"BJU Int"},{"issue":"Suppl 2","key":"10.1016\/j.eururo.2024.07.027_b0195","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1442-2042.1995.tb00475.x","article-title":"Current methods of assessing and treating carcinoma in situ of the bladder with or without involvement of the prostatic urethra","volume":"2","author":"Kurth","year":"1995","journal-title":"Int J Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0200","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s11136-016-1493-1","article-title":"How different cystoscopy methods influence patient sexual satisfaction, anxiety, and depression levels: a randomized prospective trial","volume":"26","author":"Krajewski","year":"2017","journal-title":"Qual Life Res"},{"key":"10.1016\/j.eururo.2024.07.027_b0205","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/bju.14557","article-title":"Surgical checklist impact on recurrence-free survival of patients with non-muscle-invasive bladder cancer undergoing transurethral resection of bladder tumour","volume":"123","author":"Suarez-Ibarrola","year":"2019","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2024.07.027_b0210","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.eururo.2020.04.059","article-title":"An international collaborative consensus statement on en bloc resection of bladder tumour incorporating two systematic reviews, a two-round Delphi survey, and a consensus meeting","volume":"78","author":"Teoh","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0215","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0302-2838(02)00068-4","article-title":"Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies","volume":"41","author":"Brausi","year":"2002","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0220","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.eururo.2009.05.047","article-title":"Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience","volume":"57","author":"Mariappan","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0225","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.euo.2023.07.010","article-title":"En bloc versus conventional resection of primary bladder tumor (eBLOC): a prospective, multicenter, open-label, phase 3 randomized controlled trial","volume":"6","author":"D'Andrea","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2024.07.027_b0230","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.euo.2022.05.001","article-title":"En bloc versus conventional transurethral resection of bladder tumors: a single-center prospective randomized noninferiority trial","volume":"5","author":"Gallioli","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2024.07.027_b0235","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1159\/000019859","article-title":"Significance of bladder biopsies in Ta, T1 bladder tumors: a report from the EORTC Genito-Urinary Tract Cancer Cooperative Group","volume":"35","author":"van der Meijden","year":"1999","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0240","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1442-2042.2008.02241.x","article-title":"Risk of concomitant carcinoma in situ determining biopsy candidates among primary non-muscle-invasive bladder cancer patients: retrospective analysis of 173 Japanese cases","volume":"16","author":"Hara","year":"2009","journal-title":"Int J Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0245","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.eururo.2011.10.029","article-title":"Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guerin","volume":"62","author":"Palou","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0250","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.eururo.2005.05.021","article-title":"Risk factors for mucosal prostatic urethral involvement in superficial transitional cell carcinoma of the bladder","volume":"48","author":"Mungan","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0255","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1007\/s00345-019-02673-2","article-title":"Prognostic implications of prostatic urethral involvement in non-muscle-invasive bladder cancer","volume":"37","author":"Brant","year":"2019","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0260","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1017\/S0266462310001364","article-title":"Photodynamic diagnosis of bladder cancer compared with white light cystoscopy: systematic review and meta-analysis","volume":"27","author":"Mowatt","year":"2011","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.eururo.2024.07.027_b0265","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/j.1464-410X.2009.08839.x","article-title":"Hexylaminolaevulinate fluorescence cystoscopy in patients previously treated with intravesical bacille Calmette-Guerin","volume":"105","author":"Ray","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2024.07.027_b0270","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.euros.2021.06.011","article-title":"Time to turn on the blue lights: a systematic review and meta-analysis of photodynamic diagnosis for bladder cancer","volume":"31","author":"Veeratterapillay","year":"2021","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.eururo.2024.07.027_b0275","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/bju.15723","article-title":"Blue vs white light for transurethral resection of non-muscle-invasive bladder cancer: an abridged Cochrane review","volume":"130","author":"Maisch","year":"2022","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2024.07.027_b0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.pdpdt.2022.103220","article-title":"Comparison of hexaminolevulinate (HAL)-guided versus white light transurethral resection for NMIBC: a systematic review and meta-analysis of randomized controlled trials","volume":"41","author":"Zhao","year":"2023","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"10.1016\/j.eururo.2024.07.027_b0285","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200092","article-title":"A randomized trial of photodynamic surgery in non\u2013muscle-invasive bladder cancer","volume":"1","author":"Heer","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.eururo.2024.07.027_b0290","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1080\/21681805.2017.1295101","article-title":"Clinical relevance of narrow-band imaging in flexible cystoscopy: the DaBlaCa-7 study","volume":"51","author":"Drejer","year":"2017","journal-title":"Scand J Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0295","doi-asserted-by":"crossref","first-page":"10905","DOI":"10.1038\/srep10905","article-title":"A comparison of NBI and WLI cystoscopy in detecting non-muscle-invasive bladder cancer: a prospective, randomized and multi-center study","volume":"5","author":"Ye","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.eururo.2024.07.027_b0300","doi-asserted-by":"crossref","first-page":"98","DOI":"10.4111\/icu.2018.59.2.98","article-title":"Detection and recurrence rate of transurethral resection of bladder tumors by narrow-band imaging: prospective, randomized comparison with white light cystoscopy","volume":"59","author":"Kim","year":"2018","journal-title":"Invest Clin Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0305","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.eururo.2016.03.053","volume":"70","author":"Naito","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0310","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.3390\/cancers13174378","article-title":"Performance of narrow band imaging (NBI) and photodynamic diagnosis (PDD) fluorescence imaging compared to white light cystoscopy (WLC) in detecting non-muscle invasive bladder cancer: a systematic review and lesion-level diagnostic meta-analysis","volume":"13","author":"Russo","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.eururo.2024.07.027_b0315","article-title":"Novel visualization methods assisted transurethral resection for bladder cancer: an updated survival-based systematic review and meta-analysis","volume":"11","author":"Li","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.eururo.2024.07.027_b0320","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/bju.15383","volume":"128","author":"Sari Motlagh","year":"2021","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2024.07.027_b0325","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.euo.2021.04.003","article-title":"Implications of guideline-based, risk-stratified restaging transurethral resection of high-grade Ta urothelial carcinoma on bacillus Calmette-Gu\u00e9rin therapy outcomes","volume":"5","author":"Hensley","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2024.07.027_b0330","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.eururo.2018.02.014","article-title":"Repeat transurethral resection in non-muscle-invasive bladder cancer: a systematic review","volume":"73","author":"Cumberbatch","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0335","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.euf.2016.12.011","article-title":"Role of restaging transurethral resection for T1 non-muscle invasive bladder cancer: a systematic review and meta-analysis","volume":"4","author":"Naselli","year":"2018","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2024.07.027_b0340","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1007\/s10147-019-01581-0","article-title":"The prognostic value of routine second transurethral resection in patients with newly diagnosed stage pT1 non-muscle-invasive bladder cancer: results from randomized 10-year extension trial","volume":"25","author":"Eroglu","year":"2020","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.07.027_b0345","doi-asserted-by":"crossref","first-page":"14","DOI":"10.4111\/icu.20210314","article-title":"Evaluating the efficacy of secondary transurethral resection of the bladder for high-grade Ta tumors","volume":"63","author":"Lee","year":"2022","journal-title":"Invest Clin Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0350","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.euf.2017.10.004","article-title":"Long-term outcomes from re-resection for high-risk non-muscle-invasive bladder cancer: a potential to rationalize use","volume":"5","author":"Gordon","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2024.07.027_b0355","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4103\/0974-7796.163798","article-title":"Results of second transurethral resection for high-grade T1 bladder cancer","volume":"8","author":"Hashine","year":"2016","journal-title":"Urol Ann"},{"key":"10.1016\/j.eururo.2024.07.027_b0360","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1007\/s00345-018-2299-2","article-title":"Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought","volume":"36","author":"Palou","year":"2018","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0365","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/bju.13354","article-title":"The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade\/grade 3 bladder cancer treated with bacille Calmette-Guerin","volume":"118","author":"Gontero","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2024.07.027_b0370","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/bju.13102","article-title":"Significance of the interval between first and second transurethral resection on recurrence and progression rates in patients with high-risk non-muscle-invasive bladder cancer treated with maintenance intravesical bacillus Calmette-Guerin","volume":"116","author":"Baltaci","year":"2015","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2024.07.027_b0375","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/PAP.0000000000000152","article-title":"Challenges in pathologic staging of bladder cancer: proposals for fresh approaches of assessing pathologic stage in light of recent studies and observations pertaining to bladder histoanatomic variances","volume":"24","author":"Paner","year":"2017","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.eururo.2024.07.027_b0380","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0385","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","article-title":"Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model","volume":"182","author":"Fernandez-Gomez","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0390","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","article-title":"EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1\u20133 years of maintenance bacillus Calmette-Guerin","volume":"69","author":"Cambier","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0395","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","article-title":"European Association of Urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC Guidelines Panel","volume":"79","author":"Sylvester","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0400","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.eururo.2014.06.040","article-title":"Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with bacillus Calmette-Guerin: results of a retrospective multicenter study of 2451 patients","volume":"67","author":"Gontero","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0405","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.euf.2018.12.002","article-title":"Urothelial carcinoma in bladder diverticula: a multicenter analysis of characteristics and clinical outcomes","volume":"6","author":"Voskuilen","year":"2020","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2024.07.027_b0410","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.eururo.2009.07.005","article-title":"Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer","volume":"56","author":"Dalbagni","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0415","doi-asserted-by":"crossref","first-page":"E306","DOI":"10.5489\/cuaj.1514","article-title":"Tumour stage on re-staging transurethral resection predicts recurrence and progression-free survival of patients with high-risk non-muscle invasive bladder cancer","volume":"8","author":"Bishr","year":"2014","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.eururo.2024.07.027_b0420","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.urology.2008.12.047","article-title":"Recurrence at three months and high-grade recurrence as prognostic factor of progression in multivariate analysis of T1G2 bladder tumors","volume":"73","author":"Palou","year":"2009","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2024.07.027_b0425","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.eururo.2010.05.043","article-title":"Molecular grade (FGFR3\/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer","volume":"58","author":"van Rhijn","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0430","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4103\/0974-7796.84954","article-title":"Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical bacille Calmette-Guerin","volume":"3","author":"Alkhateeb","year":"2011","journal-title":"Urol Ann"},{"key":"10.1016\/j.eururo.2024.07.027_b0435","first-page":"499","article-title":"Carcinoma in situ","volume":"19","author":"Lamm","year":"1992","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.eururo.2024.07.027_b0440","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S0022-5347(05)67974-8","article-title":"Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results","volume":"163","author":"Losa","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0445","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1016\/S0022-5347(05)64994-4","article-title":"Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance","volume":"167","author":"Griffiths","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0450","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1442-2042.2008.02012.x","article-title":"Clinical outcomes of bacillus Calmette-Guerin instillation therapy for carcinoma in situ of urinary bladder","volume":"15","author":"Takenaka","year":"2008","journal-title":"Int J Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0455","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.eururo.2011.05.033","article-title":"The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin: external validation of the EORTC risk tables","volume":"60","author":"Fernandez-Gomez","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0460","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1007\/s00432-022-04464-6","article-title":"The impact of smoking on recurrence and progression of non-muscle invasive bladder cancer: a systematic review and meta-analysis","volume":"149","author":"Slusarczyk","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.eururo.2024.07.027_b0465","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3233\/BLC-211583","article-title":"Association between smoking and overall and specific mortality in patients with bladder cancer: a population-based study","volume":"8","author":"Ho","year":"2022","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.eururo.2024.07.027_b0470","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1089\/end.2017.0154","article-title":"Holmium YAG photocoagulation: safe and economical alternative to transurethral resection in small nonmuscle-invasive bladder tumors","volume":"31","author":"Planelles Gomez","year":"2017","journal-title":"J Endourol"},{"key":"10.1016\/j.eururo.2024.07.027_b0475","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.eururo.2022.08.012","volume":"83","author":"Pedersen","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0480","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.juro.2006.10.048","article-title":"Pattern of recurrence changes in noninvasive bladder tumors observed during 2 decades","volume":"177","author":"Mariappan","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0485","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)66443-9","article-title":"Stage progression in Ta papillary urothelial tumors: relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy","volume":"165","author":"Holmang","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0490","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1097\/01.ju.0000149163.08521.69","article-title":"A surveillance schedule for G1Ta bladder cancer allowing efficient use of check cystoscopy and safe discharge at 5 years based on a 25-year prospective database","volume":"173","author":"Mariappan","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0495","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/bju.13536","article-title":"Active surveillance for low-risk non-muscle-invasive bladder cancer: mid-term results from the Bladder cancer Italian Active Surveillance (BIAS) project","volume":"118","author":"Hurle","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2024.07.027_b0500","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1097\/JU.0000000000003639","article-title":"International Bladder Cancer Group intermediate-risk nonmuscle-invasive bladder cancer scoring system predicts outcomes of patients on active surveillance","volume":"210","author":"Tan","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0505","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1111\/ans.16740","article-title":"Continuous bladder irrigation after transurethral resection of non-muscle invasive bladder cancer for prevention of tumour recurrence: a systematic review","volume":"91","author":"Li","year":"2021","journal-title":"ANZ J Surg"},{"key":"10.1016\/j.eururo.2024.07.027_b0510","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.eururo.2015.05.050","volume":"69","author":"Sylvester","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0515","doi-asserted-by":"crossref","first-page":"477","DOI":"10.6004\/jnccn.2013.0060","article-title":"Perioperative intravesical chemotherapy in non-muscle-invasive bladder cancer: a systematic review and meta-analysis","volume":"11","author":"Abern","year":"2013","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.eururo.2024.07.027_b0520","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.eururo.2013.06.009","article-title":"Immediate post-transurethral resection of bladder tumor intravesical chemotherapy prevents non-muscle-invasive bladder cancer recurrences: an updated meta-analysis on 2548 patients and quality-of-evidence review","volume":"64","author":"Perlis","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0525","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1001\/jama.2018.4657","article-title":"Effect of intravesical instillation of gemcitabine vs saline immediately following resection of suspected low-grade non-muscle-invasive bladder cancer on tumor recurrence: SWOG S0337 randomized clinical trial","volume":"319","author":"Messing","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2024.07.027_b0530","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S0022-5347(01)66226-8","article-title":"The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up","volume":"155","author":"Tolley","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0535","first-page":"765","article-title":"Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis","volume":"21","author":"Huncharek","year":"2001","journal-title":"Anticancer Res"},{"key":"10.1016\/j.eururo.2024.07.027_b0540","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.eururo.2017.06.038","article-title":"Value of an immediate intravesical instillation of mitomycin C in patients with non-muscle-invasive bladder cancer: a prospective multicentre randomised study in 2243 patients","volume":"73","author":"Bosschieter","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0545","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.eururo.2008.01.015","article-title":"The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials","volume":"53","author":"Sylvester","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0550","doi-asserted-by":"crossref","first-page":"400.e7","DOI":"10.1016\/j.urolonc.2018.05.026","article-title":"An immediate, single intravesical instillation of mitomycin C is of benefit in patients with non-muscle-invasive bladder cancer irrespective of prognostic risk groups","volume":"36","author":"Bosschieter","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2024.07.027_b0555","doi-asserted-by":"crossref","first-page":"179.e9","DOI":"10.1016\/j.urolonc.2018.10.019","article-title":"The value of immediate postoperative intravesical epirubicin instillation as an adjunct to standard adjuvant treatment in intermediate and high-risk non-muscle-invasive bladder cancer: a preliminary results of randomized controlled trial","volume":"37","author":"Elsawy","year":"2019","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2024.07.027_b0560","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.euf.2018.08.019","article-title":"Systematic review on the utilization of maintenance intravesical chemotherapy in the management of non-muscle-invasive bladder cancer","volume":"4","author":"Tabayoyong","year":"2018","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2024.07.027_b0565","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/jnci\/93.8.597","article-title":"Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial","volume":"93","author":"Au","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2024.07.027_b0570","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/bju.15571","article-title":"Intravesical mitomycin C (MMC) and MMC\u00a0+\u00a0cytosine arabinoside for non-muscle-invasive bladder cancer: a randomised clinical trial","volume":"129","author":"Miyata","year":"2022","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2024.07.027_b0575","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1464-410X.1989.tb05159.x","article-title":"Recurrence of superficial bladder carcinoma after intravesical instillation of mitomycin-C. Comparison of exposure times","volume":"63","author":"Giesbers","year":"1989","journal-title":"Br J Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0580","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.eururo.2003.12.010","volume":"45","author":"Kuroda","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0585","doi-asserted-by":"crossref","DOI":"10.3389\/fsurg.2021.775527","article-title":"Intravesical chemohyperthermia vs. bacillus Calmette-Guerin instillation for intermediate- and high-risk non-muscle invasive bladder cancer: a systematic review and meta-analysis","volume":"8","author":"Zhao","year":"2021","journal-title":"Front Surg"},{"key":"10.1016\/j.eururo.2024.07.027_b0590","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.eururo.2016.01.006","article-title":"Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin C versus bacillus Calmette-Guerin for adjuvant treatment of patients with intermediate- and high-risk non-muscle-invasive bladder cancer","volume":"69","author":"Arends","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0595","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.eururo.2022.08.003","article-title":"Adjuvant intravesical chemohyperthermia versus passive chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer (HIVEC-II): a phase 2, open-label, randomised controlled trial","volume":"83","author":"Tan","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0600","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.euo.2022.10.008","article-title":"Hyperthermic mitomycin C in intermediate-risk non-muscle-invasive bladder cancer: results of the HIVEC-1 trial","volume":"6","author":"Angulo","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2024.07.027_b0605","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00345-022-03928-1","article-title":"Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial","volume":"40","author":"Guerrero-Ramos","year":"2022","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0610","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(05)70472-1","article-title":"Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial","volume":"7","author":"Di Stasi","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2024.07.027_b0615","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer","volume":"56","author":"Malmstrom","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0620","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1046\/j.1464-410x.2001.02306.x","article-title":"A systematic review of intravesical bacillus Calmette-Guerin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer","volume":"88","author":"Shelley","year":"2001","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2024.07.027_b0625","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.urology.2005.12.014","article-title":"Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials","volume":"67","author":"Han","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2024.07.027_b0630","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1464-410X.2003.04655.x","article-title":"Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials","volume":"93","author":"Shelley","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2024.07.027_b0635","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","article-title":"Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity","volume":"169","author":"Bohle","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0640","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.eururo.2009.09.038","article-title":"Bacillus Calmette-Guerin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study","volume":"57","author":"Duchek","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0645","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.eururo.2009.04.009","volume":"56","author":"Jarvinen","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0650","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","volume":"57","author":"Sylvester","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0655","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin versus mitomycin C for Ta and T1 bladder cancer","volume":"1","author":"Schmidt","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eururo.2024.07.027_b0660","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0665","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/01.coc.0000135570.37287.7f","article-title":"The influence of intravesical therapy on progression of superficial transitional cell carcinoma of the bladder: a metaanalytic comparison of chemotherapy versus bacilli Calmette-Guerin immunotherapy","volume":"27","author":"Huncharek","year":"2004","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.07.027_b0670","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.juro.2017.01.086","article-title":"Efficacy of bacillus Calmette-Guerin strains for treatment of nonmuscle invasive bladder cancer: a systematic review and network meta-analysis","volume":"198","author":"Boehm","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0675","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.urolonc.2016.11.016","article-title":"Bacillus Calmette-Guerin strain may not effect recurrence-free survival when used intravesically with interferon-alpha2b for non-muscle-invasive bladder cancer","volume":"35","author":"Steinberg","year":"2017","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2024.07.027_b0680","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0302-2838(03)00357-9","article-title":"Maintenance bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group phase III trial","volume":"44","author":"van der Meijden","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0685","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1111\/bju.14793","article-title":"The epidemiology of bacille Calmette-Gu\u00e9rin infections after bladder instillation from 2002 through 2017: a nationwide retrospective cohort study","volume":"124","author":"Larsen","year":"2019","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2024.07.027_b0690","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.eururo.2013.07.021","volume":"65","author":"Brausi","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0695","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/bju.13474","volume":"118","author":"Oddens","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2024.07.027_b0700","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.acuro.2017.10.003","article-title":"Safety and efficacy of various strains of bacille Calmette-Guerin in the treatment of bladder tumours in standard clinical practice","volume":"42","author":"Unda-Urzaiz","year":"2018","journal-title":"Actas Urol Esp"},{"key":"10.1016\/j.eururo.2024.07.027_b0705","doi-asserted-by":"crossref","first-page":"67435","DOI":"10.18632\/oncotarget.11883","article-title":"Detection of multiple mutations in urinary exfoliated cells from male bladder cancer patients at diagnosis and during follow-up","volume":"7","author":"Critelli","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.eururo.2024.07.027_b0710","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.juro.2011.10.032","article-title":"Intravesical bacillus Calmette-Guerin outcomes in patients with bladder cancer and asymptomatic bacteriuria","volume":"187","author":"Herr","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0715","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/j.euf.2022.06.002","article-title":"Effect of levofloxacin on the efficacy and adverse events in intravesical bacillus Calmette-Guerin treatment for bladder cancer: results of a randomized, prospective, multicenter study","volume":"8","author":"Numakura","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2024.07.027_b0720","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0725","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.urology.2003.11.049","article-title":"Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression","volume":"63","author":"Bohle","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2024.07.027_b0730","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.eururo.2020.04.066","volume":"78","author":"Grimm","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0735","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guerin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0740","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1097\/01.ju.0000173919.28835.aa","article-title":"Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial","volume":"174","author":"Martinez-Pineiro","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0745","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.eururo.2007.04.062","volume":"52","author":"Ojea","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0750","doi-asserted-by":"crossref","first-page":"140","DOI":"10.4111\/icu.20210340","article-title":"Low-dose versus standard-dose bacille Calmette-Guerin for non-muscle-invasive bladder cancer: systematic review and meta-analysis of randomized controlled trials","volume":"63","author":"Choi","year":"2022","journal-title":"Invest Clin Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0755","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.eururo.2014.09.026","volume":"67","author":"Solsona","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0760","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000002572","article-title":"Combination of intravesical chemotherapy and bacillus Calmette-Guerin versus bacillus Calmette-Guerin monotherapy in intermediate- and high-risk nonmuscle invasive bladder cancer: a systematic review and meta-analysis","volume":"95","author":"Cui","year":"2016","journal-title":"Medicine"},{"key":"10.1016\/j.eururo.2024.07.027_b0765","first-page":"121","article-title":"Combination of intravesical bacille Calmette-Guerin and chemotherapy vs. bacille Calmette-Guerin alone in non-muscle invasive bladder cancer: a meta-analysis. Front","volume":"9","author":"Huang","year":"2019","journal-title":"Oncol"},{"key":"10.1016\/j.eururo.2024.07.027_b0770","article-title":"Intravesical bacillus Calmette-Guerin with interferon-alpha versus intravesical bacillus Calmette-Guerin for treating non-muscle-invasive bladder cancer","volume":"3","author":"Shepherd","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eururo.2024.07.027_b0775","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.eururo.2015.02.022","volume":"68","author":"Jarvinen","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0780","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.eururo.2016.03.034","article-title":"Intravesical bacillus Calmette-Guerin versus combination of epirubicin and interferon-alpha2a in reducing recurrence of non-muscle-invasive bladder carcinoma: FinnBladder-6 study","volume":"70","author":"Marttila","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0785","doi-asserted-by":"crossref","first-page":"269","DOI":"10.18632\/oncotarget.852","article-title":"Preclinical analyses of intravesical chemotherapy for prevention of bladder cancer progression","volume":"4","author":"Delto","year":"2013","journal-title":"Oncotarget"},{"key":"10.1016\/j.eururo.2024.07.027_b0790","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/JU.0000000000002740","article-title":"Sequential intravesical gemcitabine and docetaxel for bacillus Calmette-Gu\u00e9rin-na\u00efve high-risk nonmuscle-invasive bladder cancer","volume":"208","author":"McElree","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0795","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/01.ju.0000162059.64886.1c","article-title":"Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials","volume":"174","author":"Sylvester","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0800","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1080\/21681805.2016.1210672","article-title":"Seventeen-year follow-up of the prospective randomized Nordic CIS study: BCG monotherapy versus alternating therapy with mitomycin C and BCG in patients with carcinoma in situ of the urinary bladder","volume":"50","author":"Kaasinen","year":"2016","journal-title":"Scand J Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0805","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0022-5347(01)66338-9","article-title":"Extravesical involvement in patients with bladder carcinoma in situ: biological and therapy implications","volume":"155","author":"Solsona","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0810","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.1464-410X.2009.08417.x","article-title":"Meta-analysis: does lidocaine gel before flexible cystoscopy provide pain relief?","volume":"104","author":"Aaronson","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2024.07.027_b0815","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.urology.2006.05.059","article-title":"Urothelial carcinoma of the prostate","volume":"69","author":"Palou","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2024.07.027_b0820","first-page":"883","article-title":"The benefit of a neoadjuvant instillation of chemotherapy in non-muscle invasive bladder cancer: interim analysis of the PRECAVE randomized clinical trial","volume":"74","author":"Carrion","year":"2021","journal-title":"Arch Esp Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0825","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/JU.0000000000003002","article-title":"Clinical efficacy of neoadjuvant intravesical mitomycin-C therapy immediately before transurethral resection of bladder tumor in patients with nonmuscle-invasive bladder cancer: preliminary results of a prospective, randomized phase II study","volume":"209","author":"Lee","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0830","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/bju.15038","article-title":"CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin-C vs surgical management in low-risk non-muscle-invasive bladder cancer","volume":"125","author":"Mostafid","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2024.07.027_b0835","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1200\/JCO.22.00470","article-title":"DaBlaCa-13 study: oncological outcome of short-term, intensive chemoresection with mitomycin in nonmuscle invasive bladder cancer: primary outcome of a randomized controlled trial","volume":"41","author":"Lindgren","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.07.027_b0840","doi-asserted-by":"crossref","first-page":"108.e1","DOI":"10.1016\/j.urolonc.2014.02.020","article-title":"BCG-refractory vs. BCG-relapsing non-muscle-invasive bladder cancer: a prospective cohort outcomes study","volume":"33","author":"Herr","year":"2015","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2024.07.027_b0845","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","article-title":"Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group","volume":"34","author":"Kamat","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.07.027_b0850","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.eururo.2021.12.005","article-title":"International Bladder Cancer Group consensus statement on clinical trial design for patients with bacillus Calmette-Gu\u00e9rin-exposed high-risk non-muscle-invasive bladder cancer","volume":"82","author":"Roumigui\u00e9","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0855","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/bju.13088","article-title":"Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer","volume":"117","author":"Cockerill","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2024.07.027_b0860","article-title":"Intravesical gemcitabine for non-muscle invasive bladder cancer","volume":"1","author":"Jones","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eururo.2024.07.027_b0865","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1186\/s12885-018-5134-7","article-title":"ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk \u201cBCG failure\u201d non muscle invasive bladder cancer: 3 years follow-up outcomes","volume":"18","author":"Racioppi","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.eururo.2024.07.027_b0870","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.eururo.2018.09.005","volume":"75","author":"Tan","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0875","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.juro.2014.09.109","article-title":"Efficacy and safety of MCNA in patients with nonmuscle invasive bladder cancer at high risk for recurrence and progression after failed treatment with bacillus Calmette-Guerin","volume":"193","author":"Morales","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0880","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.urolonc.2005.11.026","article-title":"Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer","volume":"24","author":"Joudi","year":"2006","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2024.07.027_b0885","first-page":"44","article-title":"FDA approves pembrolizumab for BCG-unresponsive NMIBC","volume":"34","author":"Wright","year":"2020","journal-title":"Oncology"},{"key":"10.1016\/j.eururo.2024.07.027_b0890","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1200\/JCO.2017.72.3064","article-title":"Intravesical rAd-IFNalpha\/Syn3 for patients with high-grade, bacillus Calmette-Guerin-refractory or relapsed non-muscle-invasive bladder cancer: a phase II randomized study","volume":"35","author":"Shore","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.07.027_b0895","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.urolonc.2017.07.005","article-title":"An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: interim results","volume":"36","author":"Packiam","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2024.07.027_b0900","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2024.07.027_b0905","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2024.07.027_b0910","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.euo.2020.02.006","article-title":"Evidence-based assessment of current and emerging bladder-sparing therapies for non-muscle-invasive bladder cancer after bacillus Calmette-Guerin therapy: a systematic review and meta-analysis","volume":"3","author":"Kamat","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2024.07.027_b0915","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.juro.2011.04.073","article-title":"Factors affecting response to bacillus Calmette-Guerin plus interferon for urothelial carcinoma in situ","volume":"186","author":"Rosevear","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0920","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.eururo.2005.03.021","article-title":"Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor","volume":"48","author":"Huguet","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0925","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.eururo.2009.09.024","article-title":"Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort","volume":"57","author":"Fritsche","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0930","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/j.1464-410X.2010.09628.x","article-title":"Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort","volume":"107","author":"Svatek","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2024.07.027_b0935","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/bju.13146","article-title":"Comparing long-term outcomes of primary and progressive carcinoma invading bladder muscle after radical cystectomy","volume":"117","author":"Moschini","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2024.07.027_b0940","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.juro.2014.09.092","article-title":"Clinical outcomes of cT1 micropapillary bladder cancer","volume":"193","author":"Willis","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0945","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.juro.2006.11.090","article-title":"Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer","volume":"177","author":"Raj","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0950","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.eururo.2012.05.008","article-title":"Follow-up after surgical treatment of bladder cancer: a critical analysis of the literature","volume":"62","author":"Soukup","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0955","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/bju.14368","article-title":"Evaluating patient-reported outcome measures (PROMs) for bladder cancer: a systematic review using the COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) checklist","volume":"122","author":"Mason","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2024.07.027_b0960","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2020.03.043","article-title":"Propensity for quality: no longer a tenuous proposition in bladder cancer","volume":"78","author":"Mariappan","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0965","series-title":"Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics","author":"European Medicines Agency","year":"2019"},{"key":"10.1016\/j.eururo.2024.07.027_b0970","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1097\/01.ju.0000062605.92268.c6","article-title":"Defining bacillus Calmette-Guerin refractory superficial bladder tumors","volume":"169","author":"Herr","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0975","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.urology.2005.06.135","article-title":"High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder","volume":"66","author":"Sylvester","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2024.07.027_b0980","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1159\/000049765","article-title":"Intravesical BCG in patients with carcinoma in situ of the urinary bladder: long-term results of EORTC GU Group phase II protocol 30861","volume":"40","author":"Jakse","year":"2001","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0985","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.eururo.2011.05.045","article-title":"Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review","volume":"60","author":"van den Bosch","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.07.027_b0990","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.eursup.2008.08.001","article-title":"Clinical practice recommendations for the prevention and management of intravesical therapy-associated adverse events","volume":"7","author":"Witjes","year":"2008","journal-title":"Eur Urol Suppl"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283824025144?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283824025144?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T18:48:13Z","timestamp":1733856493000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283824025144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":198,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0302283824025144"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2024.07.027","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"European Association of Urology Guidelines on Non\u2013muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)\u2014A Summary of the 2024 Guidelines Update","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2024.07.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}